Vertex granted Market Authorization for ORKAMBI in Canada
Vertex Pharmaceuticals announced that Health Canada has granted Market Authorization for ORKAMBI to include use in children ages 2 through 5 years with cystic fibrosis who have two copies of the F508del CFTR mutation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.